A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Trial Profile

A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Neratinib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Jul 2017 Primary endpoint (Part I only: Overall clinical activity (CR+PR+SD6months) of neratinib alone in patients with metastatic HER2- breast cancer that carry HER2 mutation) has been met as per the Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 05 Jul 2017 Results (n=16) of part 1, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top